Stock Watch: Can Acadia’s Rett Syndrome Drug Succeed?
Might Trofinetide’s Clinical Efficacy Be Eclipsed By Safety Profile?
In a rare disease indication, clinical trial efficacy in Phase III should be the ticket to successful sales. But safety issues warrant careful consideration.
You may also be interested in...
The FDA’s rejection of Acadia’s label expansion into a broader patient population for its only approved drug resulted in an aggrieved reaction. Better disclosure from both sides would have helped.
Typically, state intervention in pharmaceuticals is aimed at drug cost control which, if taken to extremes, can border on nationalism.
A slow start to the year in health care is usually tempered by announcements that build up to investor conference season. However, early 2022’s plethora of negative announcements may continue biotech’s unloved status of 2021.